About MEAJO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions to authors | Online submission | Subscribe | Advertise | Contact | Login 
Middle East African Journal of Ophthalmology Middle East African Journal of Ophthalmology
Users Online: 1225   Home Print this page Email this page Small font sizeDefault font sizeIncrease font size
Year : 2015  |  Volume : 22  |  Issue : 3  |  Page : 340-345

Corneal collagen cross-linking in the treatment of progressive keratoconus: A randomized controlled contralateral eye study

1 Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran
2 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, International Campus, Tehran, Iran
3 Department of Epidemiology, Faculty of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence Address:
Hassan Hashemi
Noor Eye Hospital, No 96, Esfandiar Blvd., Vali'asr Ave, Tehran, 19686-53111
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/0974-9233.159755

Rights and Permissions

Background: To assess the short-term efficacy and safety of corneal collagen cross-linking (CXL) in preventing the progression of keratoconus (KCN). Materials and Methods: This randomized controlled clinical trial enrolled 26 patients diagnosed with bilateral progressive KCN and were eligible for CXL. In each patient, one eye was randomly selected for treatment, and the contralateral eye served as the control. The patients underwent CXL with riboflavin drops and ultraviolet radiation in the treated eye. One year follow-up data are presented. Postoperatively, patients were assessed for progression of KCN, visual changes, and other findings. The main outcome measures were maximum simulated keratometry (K-max), best spectacle-corrected visual acuity (BSCVA), and average simulated keratometry. P <0.05 was considered as statistically significant. Results: In the treated eyes, the mean K-max values decreased by 0.22 D at 1-year postoperatively and increased by 0.41 D in the control group. This difference was statistically significant (P < 0.001). BSCVA improved slightly (a decrease of 0.13 LogMAR) and decreased slightly in the control group (a 0.01 LogMAR increase). The difference between groups was statistically significant (P = 0.014). There was no decrease in visual acuity attributable to complications of CXL in the treated eyes. At 1-year, the keratometry in 3 (12%) treated eyes increased by more than 0.50 D and were considered cases of failed treatment. Conclusion: Preliminary and 1-year results indicate CXL can halt the progression of KCN in most cases without causing serious complications.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded207    
    Comments [Add]    

Recommend this journal